NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 5 FDA
NCT06993844 2026-03-17Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsEnsem TherapeuticsPhase 1/2 Recruiting233 enrolled
NCT06128551 2026-02-10Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1/2 Recruiting534 enrolled
NCT04104776 2025-05-15A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartisPhase 1/2 Recruiting275 enrolled